{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:20:52Z","timestamp":1793924452992,"version":"4.8.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:p>Among dermatologic adverse events induced by immune checkpoint inhibitors (ICI), drug reactions with eosinophilia and systemic symptoms (DRESS) have been very rarely reported. The objective of this study is to better define the clinical and histologic features, treatment and prognosis of ICI-related DRESS. This retrospective case series was conducted between 01 January 2015 and 31 December 2021 by the dermatology departments of five international networks involved in drug reactions. Inclusion criteria were age \u226518\u2009years old, DRESS with Regiscar score \u22654 (probable or certain) and ICI as a suspect drug. Clinical, biologic and follow-up data were extracted from the medical charts. Thirteen patients were included. The median time to onset was 22\u2009days (3\u201311). No patients had a high-risk drug introduced in the past 3\u2009months. A majority of patients presented fever (92%), diffuse exanthema (77%) and facial edema (69%). Biologic features included hypereosinophilia in eight patients (61.5%), hyperlymphocytosis in 3 (23%), elevated liver function tests in 11 (85%, grade 1 or 2 in most cases) and renal involvement in 5 (38%). Two patients (15%) had lung involvement. PCR evidence of viral replication was detected in five patients (38.5%). Treatment involved discontinuation of the suspect ICI and systemic steroids with variable dose and duration regimens. Among the four patients in which ipilimumab\u2009+\u2009nivolumab combination therapy was initially suspected, one was rechallenged with nivolumab monotherapy with good tolerance. Five patients were switched to another anti-PD-1 plus low-dose systemic steroids, with good tolerance in four cases. No patient died because of DRESS. DRESS induced by ICI are rare and of moderate severity. A consensus for management is still pending.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000877","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T15:01:45Z","timestamp":1675782105000},"page":"155-158","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases"],"prefix":"10.1097","volume":"33","author":[{"given":"Saskia","family":"Ingen-Housz-Oro","sequence":"first","affiliation":[{"name":"Dermatology Department, AP-HP, Henri Mondor Hospital"},{"name":"Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Cr\u00e9teil"},{"name":"FISARD group, Paris"},{"name":"University Paris est Cr\u00e9teil EpidermE, Cr\u00e9teil, France"},{"name":"EADV European Task Force \u2018Dermatology for cancer patients\u2019"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Milpied","sequence":"additional","affiliation":[{"name":"Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Cr\u00e9teil"},{"name":"FISARD group, Paris"},{"name":"EADV European Task Force \u2018Dermatology for cancer patients\u2019"},{"name":"ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris"},{"name":"Dermatology Department, CHU Bordeaux, Bordeaux"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Bensaid","sequence":"additional","affiliation":[{"name":"Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Cr\u00e9teil"},{"name":"FISARD group, Paris"},{"name":"ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris"},{"name":"Dermatology Department, CHU Edouard Herriot, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Elshot","sequence":"additional","affiliation":[{"name":"EADV European Task Force \u2018Dermatology for cancer patients\u2019"},{"name":"Department of Dermatology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek"},{"name":"Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Charlotte","family":"Br\u00fcggen","sequence":"additional","affiliation":[{"name":"ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris"},{"name":"Department of Dermatology, University Hospital Zurich"},{"name":"Faculty of Medicine, University Zurich, Zurich"},{"name":"Christine K\u00fchne-Center for Allergy Research and Education, Davos, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Starace","sequence":"additional","affiliation":[{"name":"EADV European Task Force \u2018Dermatology for cancer patients\u2019"},{"name":"Dermatology -IRCCS Policlinico di Sant\u2019Orsola, Department of Experimental, Diagnostic and Specialty Medicine (DIMES) Alma Mater Studiorum University of Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin H.","family":"Kaffenberger","sequence":"additional","affiliation":[{"name":"EADV European Task Force \u2018Dermatology for cancer patients\u2019"},{"name":"Dermatology Department, Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Carrera","sequence":"additional","affiliation":[{"name":"EADV European Task Force \u2018Dermatology for cancer patients\u2019"},{"name":"Dermatology Department, Hospital Cl\u00ednic Barcelona, University of Barcelona, Barcelona"},{"name":"CIBERER Centro de investigaciones Biomedicas en Red de Enfermedades Raras Insituto de Salud Carlos III"},{"name":"Pharmacovigilance Technical Committee Hospital Clinic Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Pham-Ledard","sequence":"additional","affiliation":[{"name":"Dermatology Department, CHU Bordeaux, Bordeaux"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azael","family":"Freites-Martinez","sequence":"additional","affiliation":[{"name":"EADV European Task Force \u2018Dermatology for cancer patients\u2019"},{"name":"Oncodermatology Clinic, Hospital Ruber Juan Bravo and Universidad Europea, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Sanchez-Pena","sequence":"additional","affiliation":[{"name":"Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Cr\u00e9teil"},{"name":"FISARD group, Paris"},{"name":"Pharmacovigilance Department, CHU Bordeaux, Bordeaux"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Lebrun-Vignes","sequence":"additional","affiliation":[{"name":"Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Cr\u00e9teil"},{"name":"FISARD group, Paris"},{"name":"Pharmacovigilance Department, AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars E.","family":"French","sequence":"additional","affiliation":[{"name":"ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris"},{"name":"Department of Dermatology and Allergy, University Hospital, Ludwig Maximilan University (LMU) Munich, Munich, Germany"},{"name":"Dr. Philip Frost, Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[{"name":"EADV European Task Force \u2018Dermatology for cancer patients\u2019"},{"name":"Department of Oncodermatology, Claudius Regaud Institute and University Cancer Institute Toulouse Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"R1-20250528","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/jdv.17855","article-title":"European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force \u2018Dermatology for cancer patients\u2019 position statement.","volume":"36","author":"Apalla","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R2-20250528","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/CMR.0000000000000819","article-title":"Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases.","volume":"32","author":"Ingen-Housz-Oro","year":"2022","journal-title":"Melanoma Res"},{"key":"R3-20250528","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/CMR.0000000000000326","article-title":"Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome.","volume":"27","author":"Mirza","year":"2017","journal-title":"Melanoma Res"},{"key":"R4-20250528","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jdcr.2018.11.017","article-title":"Nivolumab-associated DRESS syndrome: a case report.","volume":"5","author":"Lu","year":"2019","journal-title":"JAAD Case Rep"},{"key":"R5-20250528","doi-asserted-by":"crossref","first-page":"e002879","DOI":"10.1136\/jitc-2021-002879","article-title":"Nivolumab-associated DRESS in a genetic susceptible individual.","volume":"9","author":"Ai","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"R6-20250528","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/pde.14940","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms following nivolumab and ipilimumab in a pediatric patient with melanoma.","volume":"39","author":"Aljundi","year":"2022","journal-title":"Pediatr Dermatol"},{"key":"R7-20250528","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"R8-20250528","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","article-title":"Severe cutaneous adverse reactions to drugs.","volume":"390","author":"Duong","year":"2017","journal-title":"Lancet"},{"key":"R9-20250528","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.alit.2019.03.006","article-title":"Drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019.","volume":"68","author":"Shiohara","year":"2019","journal-title":"Allergol Int"},{"key":"R10-20250528","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/bjd.21781","article-title":"Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.","volume":"187","author":"Nikolaou","year":"2022","journal-title":"Br J Dermatol"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:44:16Z","timestamp":1748468656000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000877","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,6]]}}}